In commercial wean-to-finish swine production units, where castration-site inflammation and tail-bite lesion exudate accumulation are documented across multiple production cycles, the incorporation of Shengji Powder veterinary-grade API into Type B medicated feed premixes follows a sequence of unit operations governed by 21 CFR 225.1–225.202 and VICH GL18 residual-solvent limits for veterinary medicinal products. The API, supplied as a standardized fine powder with a particle-size distribution of 95% passing through an 80-mesh sieve (equivalent to ≤177 µm aperture), is first pre-blended with a carrier substrate—typically ground limestone or rice hulls at a 1:10 geometric dilution ratio—to mitigate segregation during subsequent mixing. The use of a ribbon blender with a working capacity of 500–2000 L and an agitator speed of ≤25 rpm minimizes shear-induced degradation of heat-labile glycoside constituents. Addition ratios for Type B premix typically range from 0.5% to 2.0% w/w, corresponding to a final feed inclusion rate of 50–200 g API per tonne of complete feed, although published pharmacokinetic data for granulation-tissue-promoting botanical APIs in feed matrices is limited, and batch-level homogeneity testing according to Chinese Veterinary Pharmacopoeia (2020 edition) Appendix 0931 is required to confirm distribution uniformity with a relative standard deviation ≤5.0% across 10 sampling points. Compliance for export into the European Union requires documentation under Regulation (EU) 2019/6 Annex I for the active substance master file, with residues evaluated according to the maximum residue limit framework established by Regulation (EC) No 470/2009. The downstream production process for the final premix product involves three phases: (1) carrier pre-blending for 15–20 minutes, (2) addition of the API-carrier pre-blend followed by an additional 20–30 minutes of mixing, and (3) discharge through a 1.5 mm aperture safety sifter prior to packaging in 25 kg multi-wall paper bags with an inner polyethylene liner. Terminal products derived from this process include Type B medicated feed premixes for on-farm mixing, oral top-dress powders for addition to individual rations, and concentrated water-dispersible powders for use in weaning-stage creep feed. Processing limitations include the requirement to maintain moisture content below 8.0% w/w during blending, as hygroscopic constituents absorb ambient humidity above 60% relative humidity and initiate particle agglomeration. Additionally, the API must not be combined with oxidizing disinfectants (e.g., hypochlorite-based sanitizers) during equipment cleaning, as residual oxidant traces drive degradation of phenolic marker compounds. On production-scale feed mills with bucket elevators and drag conveyors, observed batch-to-batch variance in API homogeneity is primarily attributable to electrostatic charge accumulation on the carrier substrate at ambient relative humidity below 30%; installation of in-line grounding straps and humidification to 45–55% relative humidity addresses this operational bottleneck.Post-Surgical Recovery Formulations in Companion Animal PracticeWhen veterinary formulators evaluate the compatibility of Shengji Powder API with direct compression excipients for canine and feline postoperative recovery formulations, the mechanical and chemical properties of the API dictate specific process adjustments. The API exhibits moderate hygroscopicity (equilibrium moisture content of 6.0–8.0% w/w at 55% relative humidity and 25°C), which requires pre-drying in a tray dryer at 60°C for 4 hours when ambient relative humidity exceeds 60% prior to batch weighing. Tablet formulation addition ratios typically fall within 10–20% w/w of the tablet core, with the remainder composed of microcrystalline cellulose (Ph. Eur. grade), croscarmellose sodium at 3–5% w/w as a disintegrant, and magnesium stearate at 0.5–1.0% w/w as a lubricant. Wet granulation is preferred over direct compression because the API's platelet-like particle morphology produces poor flowability (Carr's compressibility index commonly exceeding 25%). The granulation step employs a high-shear mixer granulator with a PVP K30 binder solution at 3–5% w/v in purified water, added dropwise until a granule endpoint of 60–70% w/w mass distribution between 180 µm and 710 µm mesh cuts is achieved. Fluid-bed drying at an inlet air temperature of 55–65°C reduces granule moisture to below 3.0% w/w, after which compression is performed on a rotary tablet press at compression forces of 8–15 kN with a target tablet hardness of 60–90 N. Compliance for this dosage form is anchored to the Chinese Veterinary Pharmacopoeia (2020 edition) general monograph for tablets, USP-NF General Chapter <905> for content uniformity (acceptance value L1 ≤15.0), and 21 CFR 211 subpart E for equipment and process control. Capsule presentations, where the API is blended at 15–25% w/w of the fill weight, require the same granulation step but are filled into hard gelatin capsules size 2 or 3 using an automatic capsule filling machine at speeds of 30,000–60,000 capsules per hour. Terminal products include 100–500 mg tablets for postoperative tissue repair in companion animals and 250 mg capsules for adjunctive wound management. Operational incompatibilities include the avoidance of formulation combinations with high-moisture excipients (e.g., sorbitol above 10% w/w) due to premature granule softening and the exclusion of amine-based film-coating polymers, which have been observed to induce discoloration of the API through Maillard-type reactions during pan coating at inlet temperatures above 65°C.Predominantly, dairy operations in temperate climates document interdigital dermatitis and post-calving cervical tissue trauma as the two wound categories most frequently addressed through oral granulation-promoting bolus formulations. The API is incorporated into extrusion-spheronization granule matrices at 5–15% w/w alongside lactose monohydrate and microcrystalline cellulose, producing intraruminal granules with a dissolution lag time of 45–90 minutes as per Chinese Veterinary Pharmacopoeia (2020 edition) Appendix 0931. Terminal products for this segment include 10 g oral granules and intraruminal sustained-release boluses, with compliance documentation maintained under Regulation (EU) 2019/6 and stability testing conducted according to VICH GL27 at 25°C/60% relative humidity for 24 months.What Limits Injection Feasibility in Aqueous Veterinary Formulations?The aqueous solubility profile of crude botanical APIs dictates that injectable presentations of Shengji Powder require upstream purification or solubilization strategies before terminal sterilization can be performed. Solubility of the untreated API in water at 25°C typically falls below 2.0 mg/mL, which is insufficient for the 10–50 mg/mL target concentrations needed for injectable antimicrobial-adjunctive or tissue-repair parenteral products. Two processing routes are industrially viable. The first involves solvent fractionation: the API is refluxed in 60% v/v ethanol at a solid-to-liquid ratio of 1:8 for 3 hours, the extract is concentrated under reduced pressure at ≤50°C, and the resulting concentrate is reconstituted in water-for-injection to a final addition ratio of 0.1–0.5% w/v as purified extract. The second route employs co-solvent systems—propylene glycol:water at 40:60 v/v—allowing addition ratios up to 1.0% w/v without precipitation, though the finished product then carries a co-solvent safety profile requiring justification in the dossier per VICH GL18. Sterilization of the injectable formulation is achieved by membrane filtration through a 0.45 µm pre-filter followed by a 0.22 µm sterilizing-grade filter, as thermal sterilization by autoclave at 121°C for 15 minutes is known to degrade the API's marker glycosides by 25–40% as determined by HPLC peak-area analysis. Aseptic filling into 10 mL or 50 mL Type I glass vials is performed under laminar airflow in an ISO 5 cleanroom. Compliance for this dosage form requires sterility testing according to USP <71>, bacterial endotoxin limits below 0.5 EU/mg as per USP <85>, and a pH stability window of 5.5–7.5 as documented in Chinese Veterinary Pharmacopoeia (2020 edition) injectable-product requirements. Terminal products include aqueous injectable solutions for postoperative recovery support in large animals and lyophilized powders for reconstitution in sterile water, with the lyophilization performed at a shelf temperature of −30°C for primary drying and +20°C for secondary drying over a 48-hour cycle. Processing boundaries include pH drift during accelerated stability testing: when formulated at pH below 5.0, the API exhibits hydrolytic cleavage of ester-linked constituents, observed as a 15% loss of marker compound peak area after 12 weeks at 40°C/75% relative humidity. Batch-to-batch variability in the injectable product is controlled by specifying a minimum purity of 85% total marker glycosides for the API input, with any lot falling below this threshold rejected for parenteral use.Thermal Degradation Kinetics During Fluid-Bed Granulation of Premix BlendsAt inlet air temperatures exceeding 70°C, degradation of thermolabile marker glycosides in Shengji Powder API proceeds through first-order kinetics with an observed half-life of approximately 90 minutes at 70°C and 35 minutes at 80°C as determined by isothermal stress studies using HPLC-UV detection at 254 nm. This thermal ceiling imposes specific equipment limits on top-spray fluid-bed granulation processes used for coating the API onto carrier particles. The recommended process window is inlet air temperature of 55–65°C, product temperature of 38–45°C, and spray rate of 10–15 g/min for a Wurster column fitted with a 1.2 mm two-fluid nozzle. Under these conditions, the API as a 20% w/w active coating in a binder solution composed of hydroxypropyl methylcellulose E5 at 5% w/w in water is sprayed onto sucrose spheres of 500–710 µm diameter. The granulation process is terminated when the product moisture content falls below 2.5% w/w as measured by a halogen moisture analyzer. Compliance for the granulation line is maintained under ISO 9001:2015 clause 8.5.1 for production provision control, with impurity profiling conducted according to VICH GL10 and residual solvent limits per VICH GL18. Terminal products from this process include coated oral granules for administration to calves and foals, and effervescent premix powders where citric acid and sodium bicarbonate (85:15 w/w ratio) are dry-blended post-granulation. The dry-blending step following granulation must be performed in a V-blender operating at 10–15 rpm for no more than 20 minutes, as prolonged mixing of the effervescent blend above 25°C initiates premature acid-base reaction at ambient humidity above 50% relative humidity. Published data for the specific fluid-bed processing of Shengji Powder API in GMP veterinary facilities remains limited; process validation reports are therefore required from the API manufacturer and the dosage-form manufacturer, with three consecutive full-scale batches demonstrating content uniformity meeting the Chinese Veterinary Pharmacopoeia (2020 edition) granule monograph specifications.While laying-hen operations and broiler integrators routinely administer therapeutic agents through the drinking-water route, the formulation of Shengji Powder API into water-soluble presentations demands consideration of solubility kinetics, palatability, and water-line biofilm interactions. The API is micronized to a D90 of ≤20 µm via air-jet milling, blended with a wetting agent (polysorbate 80 at 0.5% w/w), and standardized to a stock-solution concentration of 0.5–1.5% w/v before dilution at 1:1000 through a medicator proportioner at the point of administration. Terminal products include 500 g and 1 kg water-soluble powders in aluminum-foil sachets and concentrated oral solutions in 1 L HDPE bottles, with stability testing according to VICH GL27 at 25°C/60% RH for 24 months.

Dosage form	Typical API addition ratio	Key acceptance criterion	Reference standard
Tablets (companion animal)	10–20% w/w of core	Content uniformity L1 ≤15.0	USP-NF <905>, CVP 2020
Capsules (companion animal)	15–25% w/w of fill	Dissolution ≥75% at 45 min	USP-NF <711>, CVP 2020
Injectable solution	0.1–0.5% w/v purified extract	Sterility, endotoxins <0.5 EU/mg	USP <71>, USP <85>
Oral granules (ruminant)	5–15% w/w	Loss on drying ≤3.0% w/w	CVP 2020, VICH GL27
Type B premix (swine)	0.5–2.0% w/w	Homogeneity RSD ≤5.0%	21 CFR 225.1–225.202
Water-soluble powder (poultry)	5–10% w/w micronized	Wettability ≤60 s	Manufacturer specification
Coated granules (fluid-bed)	20% w/w in coating layer	Granule moisture ≤2.5% w/w	CVP 2020, ISO 9001:2015

Test parameter	Test method	Acceptance limit	Analytical instrument
Content uniformity	HPLC-UV	90.0–110.0% of label claim	HPLC with C18 column
Loss on drying	CVP Appendix 0831	≤5.0% w/w	Halogen moisture analyzer
Microbial limits	CVP Appendix 1105	Total aerobic count ≤10³ CFU/g	Membrane filtration
Heavy metals	ICP-MS	Pb ≤5 ppm, As ≤2 ppm, Cd ≤1 ppm	ICP-MS
Residual solvents	GC-HS	Per VICH GL18 limits	Headspace GC
Particle size distribution	Laser diffraction	D90 ≤200 µm	Laser diffraction analyzer